

CASE 4-31830C

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV483669437 U.S.

Express Mail Label Number

5-27-05

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

MALCOLM BOYD

APPLICATION NO: 09/884,715

FILED: JUNE 19, 2001

FOR: NUCLEOSIDE ANALOGS IN COMBINATION THERAPY OF
HERPES SIMPLEX

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(617) 871-3356
Date: May 27, 2005

Regina Baulista
Regina Baulista
Attorney for Applicant
Reg. No. 46,280



CASE 4-31830C

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 483669437 U.S.

Express Mail Label Number

5-27-05

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

ART UNIT: 1648

MALCOLM BOYD

EXAMINER: MOSHER, M.

APPLICATION NO: 09/884,715

FILED: JUNE 19, 2001

FOR: NUCLEOSIDE ANALOGS IN COMBINATION THERAPY OF
HERPES SIMPLEX

MS: Amendment

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c). A letter for payment of the fee set forth in 37 C.F.R. 1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of the cited references will be provided subsequently.


06/01/2005 AMONDAF1 00000041 190134 09884715

02 FC:1806 180.00 DA

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis
Corporate Intellectual Property.
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(617) 871-3356



Regina Bautista
Attorney for Applicant
Reg. No. 46,280

Date: May 27, 2005

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

4-31830DC

APPLICATION NO. 09/884,715

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT


Malcolm Richard Boyd

FILING DATE

6/19/01

Group

1648

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	3,317,384	5/2/67				
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	AM	WO 9624355	8/15/96				<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 9111187	8/8/91				<input type="checkbox"/>	<input type="checkbox"/>
	AO	WO 9200742	1/23/92				<input type="checkbox"/>	<input type="checkbox"/>
	AP	PCT/SE95/00114	2/6/95				<input type="checkbox"/>	<input type="checkbox"/>
	AQ	GB 1,099,385	1/17/68				<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Field, et al., "Antimicrobial Agents and Chemotherapy", Vol. 39, pp. 1114-19 (1995)
	AS	Field, et al., "Antiviral Chemistry & Chemotherapy", Vol. 6, pp. 210-16 (1995)
	AT	Gluckman, et al., "Antimicrobial Chemotherapy", Vol. 12, Supp. B, pp. 161-67 (1983)

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

4-31830BC

APPLICATION NO. 09/884,715

APPLICANT


Malcolm Richard Boyd

FILING DATE

6/19/01

Group

1648

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

DA	Wade, et al., "Annals of Internal Medicine", Vol. 100, pp. 823-28 (1984)
DB	Shepp, et al, "Annals of Internal Medicine", Vol. 102, pp. 783-85 (1985)
DC	Seale, et al., "J. American Medical Association", Vol. 254, pp. 3435-38 (1985)
DD	Stoffel, et al., "Transplantation Proceedings", Vol. XIX, no. 1, pp. 2190-93 (1987)
DE	Squifflet, et al., "Transplantation Proceedings", Vol. XVII, no. 1, pp. 1212-17 (1985)
DF	Griffin, et al., "Transplantation Proceedings", Vol. XVII, no. 1, pp. 84-85 (1985)
DG	Pettersson, et al., "Transplantation", Vol. 39, pp. 279-81 (1985)
DH	Gold, et al., "Acyclovir Prophylaxis for Herpes Simplex Virus Infection", Antimicrob. Agents & Chemo., Vol. 31, pp. 361-67 (1987)
DI	Fiddian, et al., "Prevention of Herpes Simplex Virus Infections in Susceptible Patients", Infection, Vol. 15, pp. S21-25 (1987)
DJ	Saral, et al., "Management of Mucocutaneous Herpes Simplex Virus Infections in Immunocompromised Patients", Amer. J. Medicine, Vol. 85, pp. 57-60
DK	Thin, "Management of Genital Herpes Simplex Infections", Amer. J. Medicine, Vol. 85, pp. 3-6
DL	Mertz, "Genital Herpes Simplex Virus Infections", Medical Clinics of North America, Vol. 74, pp. 1433-54 (1990)
DM	Stone, et al., "Treatment of Genital Herpes", Reviews of Infectious Diseases, Vol. 12, pp. S610-619 (1990)
DN	Lietman, et al., "Antiviral Research", Suppl. 1, pp. 241-50 (1985) Proc. of 1 st Int. TNO Conf. Antiviral Res.

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO.

4-31830 **EC**

APPLICATION NO. 09/884,715

APPLICANT


Malcolm Richard Boyd

FILING DATE

6/19/01

Group

1648



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
	BL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	BM						<input type="checkbox"/>	<input type="checkbox"/>
	BN						<input type="checkbox"/>	<input type="checkbox"/>
	BO						<input type="checkbox"/>	<input type="checkbox"/>
	BP						<input type="checkbox"/>	<input type="checkbox"/>
	BQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	BR	Mindel, et al, "Recent Advances in Genital Herpes", Ann. Acad. Med. Singapore, Vol. 24, pp. 584-92 (1995)
	BS	Pollard, et al., "Cytomegalovirus Infections in Renal, Heart, Heart-lung and Liver Transplantation", Pediatric Infect. Dis. J., Vol. 7 pp. S97-102 (1988)
	BT	Sanchez-Turrion, et al., "Transplantation Proceedings", Vol. 25, pp. 1786 (1993)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.


FORM PTO-1449
(REV. 7-85)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.

4-31830 

APPLICATION NO. 09/884/715

APPLICANT

Malcolm Richard Boyd

FILING DATE

6/19/01

Group

1648

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	DA	Atkinson, et al., "British J. Haematology", Vol. 79, pp. 57-62 (1991)
	DB	Goodrich, et al., "Annals of Internal Med.", Vol. 118, pp. 173-78 (1993)
	DC	Smee, et al., "J. Infectious Diseases", Vol. 164, pp. 958-61 (1991)
	DD	
	DE	
	DF	
	DG	
	DH	
	DI	
	DJ	
	DK	
	DL	
	DM	
	DN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.